Press Release Celcuity Submits sNDA to FDA for REVTORPYKâ„¢ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer 1 hour ago
Press Release Celcuity Inc. Reports Release of Second Quarter 2026 Financial Results and Provides Corporate Update Aug 17